Conclusions
DISEASE, REMISSION
In this cohort of patients with moderate to severely active RA, SC abatacept was effective and well-tolerated, irrespective of the treatment approach used to manage the disease. The T2T approach may offer a greater likelihood of achieving CDAI LDA as well as faster achievement of SDAI remission.